SUDOSCAN has demonstrated its efficacy in the field of neurology
Peripheral neuropathy is the result of damage to peripheral nerves, including small fiber neuropathy involving small and myelinated nerves (Aδ), as well as unmyelinated nerves (unmyelinated C fibers). In peripheral neuropathy, small somatic and autonomic fibers can be affected. Small fibers control thermal perception, pain perception, and autonomic functions such as cardiac, pulmonary or enteric functions [1].
Peripheral neuropathy can be a complication of several diseases such as diabetes, neurological or metabolic disorders, and infections. It can also result from certain drugs or alcohol consumption.
This complication can occur in the very early stages of disease. Its detection may help physicians to better manage their patients and avoid advanced complications.
Small fiber neuropathies have been assessed using SUDOSCAN in different diseases and therapeutic areas. The following are some of the diseases with neurological complications where SUDOSCAN has been applied:
- Hereditary amyloidosis, AA, wild type
- Covid-19
- Hepatitis C
- Epilepsy
- Fabry disease
- Parkinson’s disease
- Autoimmune small fiber neuropathy
- Fibromyalgia
- Lewy body dimentia
- Narcolepsy
- Sjörgen’s syndrome
- Pure autonomic failure
Find the main publication list of diseases with related neurological complications click here.
Clinical application of SUDOSCAN in wild-type cardiac amyloidosis
Amyloidosis is an acquired or hereditary rare disease caused by amyloid protein deposits in organs. Several types have been reported including transthyretin hereditary amyloidosis (hATTR amyloidosis or familial amyloidosis), wild-type cardiac amyloidosis, AA amyloidosis and AL amyloidosis.
M. Kharoubi from Henri Mondor University Hospital, Paris, Pr T. Damy’s team, has published in ESC Heart Failure [2] results on screening for autonomic neuropathy in transthyretin wild-type cardiac amyloidosis (ATTRwt-CA), using SUDOSCAN. She demonstrated that SUDOSCAN feet measures (electrochemical skin conductance, ESC) were reduced in almost 50% of patients with ATTRwt-CA and were associated with a worse prognosis, thus helping identify patients at higher risk for a poor outcome. These findings in cardiac amyloidosis highlight the functional interest of SUDOSCAN in daily cardiology practice. SUDOSCAN testing could be completed by cardiologists and would allow patients with ATTRwt-CA and poor ESC to be triaged for consultation with a neurologist for further investigation, thus optimizing the management and monitoring of these patients.
SUDOSCAN Benefits
Fast
No patient preparation
Results in 3 minutes
Easy-to-read critical data points to help physicians reach a diagnosis
Secure
Non-invasive
No fasting
Easy to operate
CE and FDA approvals
Accurate
Reproducible quantitative results
Independent from environmental conditions
Backed by evidence-based research
150 peer-reviewed journals publications
References
[1] Levine TD. Small Fiber Neuropathy: Disease Classification Beyond Pain and Burning. J Cent Nerv Syst Dis.2018;10:1179573518771703. Published 2018 Apr 18.[2] Kharoubi M, Roche F, Bézard M, Hupin D, Silva S, Oghina S, Chalard C, Zaroui A, Galat A, Guendouz S, Canoui-Poitrine F, Hittinger L, Teiger E, Lefaucheur JP, Damy T. Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis. ESC Heart Fail. 2021 Apr;8(2):1656-1665.
